• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Vanda Pharmaceuticals Inc.

    6/13/25 9:40:59 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VNDA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001802653
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Vanda Pharmaceuticals Inc.
    SEC File Number
    001-34186
    Address of Issuer
    2200 Pennsylvania Avenue NW
    Suite 300E
    Washington
    DISTRICT OF COLUMBIA
    20037
    Phone
    202-734-3400
    Name of Person for Whose Account the Securities are To Be Sold
    Mitchell Stephen Ray
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Merrill Lynch
    1152 15th Street, N.W.
    Suite 6000
    Washington � DC � 20005
    7000321595893448206/13/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock06/11/2021Vesting/Settlement of Restricted Stock UnitsIssuerCheckbox not checked401506/11/2021Compensation
    Common Stock06/10/2022Vesting/Settlement of Restricted Stock UnitsIssuerCheckbox not checked230006/10/2022Compensation
    Common Stock06/16/2023Vesting/Settlement of Restricted Stock UnitsIssuerCheckbox not checked68506/16/2023Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/13/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Stephen Ray Mitchell

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $VNDA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VNDA

    DatePrice TargetRatingAnalyst
    10/31/2024$18.00Buy
    H.C. Wainwright
    7/11/2024$11.00Overweight
    Cantor Fitzgerald
    2/25/2022$24.00 → $12.00Buy → Hold
    Jefferies
    More analyst ratings

    $VNDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Vanda Pharma with a new price target

    H.C. Wainwright initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    10/31/24 6:31:19 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Vanda Pharma with a new price target

    Cantor Fitzgerald initiated coverage of Vanda Pharma with a rating of Overweight and set a new price target of $11.00

    7/11/24 7:49:37 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals downgraded by Jefferies with a new price target

    Jefferies downgraded Vanda Pharmaceuticals from Buy to Hold and set a new price target of $12.00 from $24.00 previously

    2/25/22 4:56:52 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

    Conference Call and Webcast to Follow WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 29, 2025, during which management will discuss the third quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode 8728050. The

    10/22/25 4:30:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

    Multiyear agreement includes exclusive Monumental Sports Network studio entitlement, activations across Capitals, Wizards, and Mystics, and deep integration via community and media platforms For photos of the new Vanda Pharmaceuticals Studio and video announcing the partnership, please CLICK HERE. WASHINGTON, Oct. 8, 2025 /PRNewswire/ -- Monumental Sports & Entertainment (MSE) today announced Vanda Pharmaceuticals (NASDAQ:VNDA), a leading global biopharmaceutical company headquartered in Washington, D.C., as the organization's newest Founding Partner for its next-generation arena in downtown Washington. A centerpiece of the agreement is Vanda's exclusive entitlement of the best-in-class Monu

    10/8/25 8:00:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

    WASHINGTON, Oct. 1, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it has agreed on a collaborative framework with the U.S. Food and Drug Administration (FDA) for the resolution of certain disputes regarding HETLIOZ® (tasimelteon) and tradipitant. Key features of the agreement include: The FDA will conduct an expedited re-review of the partial clinical hold preventing long term clinical studies of tradipitant for the treatment of motion sickness by November 26, 2025. The FDA will continue its review of Vanda's New Drug Application (N

    10/1/25 5:02:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    8/8/25 4:05:18 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mitchell Stephen Ray sold $32,130 worth of shares (7,000 units at $4.59), decreasing direct ownership by 7% to 97,082 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    6/16/25 9:10:04 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mitchell Stephen Ray was granted 59,225 shares, increasing direct ownership by 132% to 104,082 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    6/9/25 5:36:16 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    8/8/25 4:05:18 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    5/21/25 9:23:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    5/19/25 5:13:38 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    SEC Filings

    View All

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    10/1/25 5:10:10 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Vanda Pharmaceuticals Inc.

    10-Q - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    7/31/25 8:57:58 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    7/31/25 7:34:48 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Financials

    Live finance-specific insights

    View All

    Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

    Conference Call and Webcast to Follow WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 29, 2025, during which management will discuss the third quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode 8728050. The

    10/22/25 4:30:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

    Fanapt® Q2 2025 net product sales increased by 27% to $29.3 million compared to Q2 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, July 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2025.

    7/31/25 7:30:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

    Conference Call and Webcast to Follow WASHINGTON, July 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the second quarter 2025 on Thursday, July 31, 2025, before the market opens.  Vanda will host a conference call at 8:00 AM ET on Thursday, July 31, 2025, during which management will discuss the second quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9430387. The conf

    7/23/25 4:45:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Leadership Updates

    Live Leadership Updates

    View All

    Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

    WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent. "Tage is a highly accomplished industry leader and respected scientist with deep experience across a diverse range of therapeutic areas," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are confident that his scientific expertise and executive experience will be invaluable, and look forward to working with him as we contin

    3/17/23 7:00:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    2/13/24 5:16:07 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    2/13/24 10:53:14 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    2/9/24 9:59:19 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care